SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/05/09 -- Theravance, Inc. (NASDAQ: THRX)
today reported that an equity award was made to one new employee. Pursuant
to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity award was granted
under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which
the Board of Directors of Theravance adopted to facilitate the granting of
equity awards to new employees. In accordance with Nasdaq rules, this
grant was made under an equity incentive plan without stockholder
approval. Nasdaq rules require a public announcement of equity awards to
be made under this type of plan. One employee was granted an option to
purchase 3,000 shares of the Company's common stock, which option vests
over four years and expires in 10 years assuming continued employment. No
officers received any award under this plan. The exercise price for the
option shares granted is $13.70, which was the closing price of Theravance
common stock on the Nasdaq Global Market as such price was reported by
NASDAQ on the date of grant.
About Theravance
Theravance is a biopharmaceutical company with a pipeline of internally
discovered product candidates. Theravance is focused on the discovery,
development and commercialization of small molecule medicines across a
number of therapeutic areas including respiratory disease, bacterial
infections and gastrointestinal motility dysfunction. The company's key
programs include: telavancin for the treatment of serious Gram-positive
bacterial infections with Astellas Pharma Inc., the Horizon program and the
Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with
GlaxoSmithKline plc, and the Gastrointestinal Motility Dysfunction program.
By leveraging its proprietary insight of multivalency toward drug discovery
focused primarily on validated targets, Theravance is pursuing a next
generation strategy designed to discover superior medicines in areas of
significant unmet medical need. For more information, please visit the
company's web site at www.theravance.com.
THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE®
are registered trademarks of Theravance, Inc.
Contact Information:
Michael W. Aguiar
Senior Vice President and Chief Financial Officer
650-808-4100
Email Contact